Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma

Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma Based on Tumor Immune Microenvironment

To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2~3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.

Inclusion Criteria Before the trial, the participants must meet all of the following requirements to be eligible for inclusion.

1. Clearly diagnosed with nasopharyngeal carcinoma by pathology;
2. Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital;
3. Patients diagnosed in our hospital from January 2025 to December 2028;
4. Have relatively complete clinical data;
5. Age between 15 and 75 years old;

Exclusion Criteria Before the trial, the participants who meet any of the following requirements cannot be included.

1. The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.;
2. The participants failed to obtain pathological and imaging data for various reasons;
3. Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.